In 2017, R&D productivity of the top-30 pharmaceutical companies had decreased for the first time since 2014, according to Catenion’s annual review of the sector. This trend continued into 2018, albeit with a lower magnitude as overall R&D productivity dropped by around 10% (vs. about 15% last year).
Yet again, the major driver is a decline in the metric that looks at pipeline value versus cumulative R&D spending...